Protalix BioTherapeutics (PLX) Change in Accured Expenses (2010 - 2026)

Protalix BioTherapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $820000.0 for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 163.86% year-over-year to $820000.0 in Q1 2026; TTM through Mar 2026 was $2.4 million, a 190.07% increase from a year earlier, with the FY2025 full-year figure at $292000.0, down 58.05% from the prior year.
• Change in Accured Expenses slipped to $820000.0 in Q1 2026 per PLX's latest filing, from $4.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.3 million in Q4 2025 and bottomed at -$3.9 million in Q2 2022.
• The 5-year median for Change in Accured Expenses is $177000.0 (2023), against an average of $135235.3.
• Across the five-year window, Change in Accured Expenses jumped 503.01% in 2023 and plunged 590.96% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at -$366000.0 in 2022, then soared by 503.01% to $1.5 million in 2023, then fell by 7.39% to $1.4 million in 2024, then surged by 216.62% to $4.3 million in 2025, then slumped by 81.04% to $820000.0 in 2026.
• Per Business Quant, the three latest PLX Change in Accured Expenses figures stand at $820000.0 (Q1 2026), $4.3 million (Q4 2025), and -$2.1 million (Q3 2025).